160 related articles for article (PubMed ID: 3291982)
21. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
24. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.
Boccadoro M; Marmont F; Tribalto M; Fossati G; Redoglia V; Battaglio S; Massaia M; Gallamini A; Comotti B; Barbui T
J Clin Oncol; 1989 Jan; 7(1):119-25. PubMed ID: 2909664
[TBL] [Abstract][Full Text] [Related]
25. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of plasma cell morphology in multiple myeloma.
Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
28. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
Linkesch W; Ludwig H
Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
[TBL] [Abstract][Full Text] [Related]
29. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
30. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis.
Gertz MA; Kyle RA; Greipp PR
Blood; 1989 Aug; 74(3):1108-11. PubMed ID: 2752156
[TBL] [Abstract][Full Text] [Related]
31. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
32. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
33. Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.
Morell A; Riesen W
Acta Haematol; 1980; 64(2):87-93. PubMed ID: 6159767
[TBL] [Abstract][Full Text] [Related]
34. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
Bataille R; Grenier J; Sany J
Blood; 1984 Feb; 63(2):468-76. PubMed ID: 6362753
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy.
Bartl R; Frisch B; Diem H; Mündel M; Fateh-Moghadam A
Eur J Haematol Suppl; 1989; 51():88-98. PubMed ID: 2697597
[TBL] [Abstract][Full Text] [Related]
36. Beta 2 microglobulin serum levels and prediction of survival in AL amyloidosis.
Zerbini CA; Anderson JJ; Kane KA; Ju ST; Campistol JM; Simms RW; Cohen AS; Skinner M
Amyloid; 2002 Dec; 9(4):242-6. PubMed ID: 12557752
[TBL] [Abstract][Full Text] [Related]
37. Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis?
Boccadoro M; Gallone G; Frieri R; Pileri A; Bataille R; Klein B
Blood; 1993 Dec; 82(11):3507-8. PubMed ID: 8241520
[No Abstract] [Full Text] [Related]
38. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
39. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
[TBL] [Abstract][Full Text] [Related]
40. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]